Trials / Recruiting
RecruitingNCT07127874
A Study of PHN-012 in Patients With Advanced Solid Tumors
First-in-Human, Phase 1 Study of PHN-012, an Antibody Drug Conjugate, in Patients With Advanced Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 165 (estimated)
- Sponsor
- Pheon Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This first-in-human study will evaluate safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of PHN-012, a novel antibody-drug conjugate (ADC), in patients with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PHN-012 | PHN-012 is an ADC |
Timeline
- Start date
- 2025-09-23
- Primary completion
- 2027-09-01
- Completion
- 2028-05-01
- First posted
- 2025-08-17
- Last updated
- 2026-04-17
Locations
21 sites across 2 countries: United States, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07127874. Inclusion in this directory is not an endorsement.